GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aurobindo Pharma Ltd

Aurobindo Pharma Q1 FY26: Profit After Tax at ₹7,372.2 million; Merger Scheme Approved

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 05 Aug 2026, 07:52 PM IST  ·  BSE ID: d53e759e-0d15-4439-925b-d50e179f50d2
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma reported its latest quarterly financial results and announced a plan to merge three of its subsidiary companies.
🤖 AI Summary
  • Aurobindo Pharma's Board approved standalone Q1 FY26 results with Profit After Tax of ₹7,372.2 million.
  • Consolidated Profit After Tax for Q1 FY26 stood at ₹19,977.8 million, showing a year-on-year increase.
  • The Board approved a Scheme of Amalgamation for three wholly-owned subsidiaries: Eugia Steriles, Eugia SEZ, and Eugia Pharma Specialities.
  • Standalone revenue from operations for Q1 FY26 was ₹27,995.1 million, a decline from ₹28,481.7 million year-on-year.
  • Consolidated revenue from operations for Q1 FY26 reached ₹91,503.5 million, up from ₹78,681.4 million year-on-year.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Standalone Profit After Tax Q1 FY26
₹7,372.2 million
31.85%
Consolidated Profit After Tax Q1 FY26
₹19,977.8 million
27.21%
Standalone Revenue from Operations Q1 FY26
₹27,995.1 million
-1.71%
Consolidated Revenue from Operations Q1 FY26
₹91,503.5 million
16.30%
Standalone Basic EPS Q1 FY26
₹12.75
32.40%
🏢 How This Affects the Company
📈
Business Impact
The proposed scheme of amalgamation consolidates three subsidiaries under Eugia Pharma Specialities Limited, streamlining the corporate structure related to sterile and SEZ operations.
💰
Financial Impact
Standalone Profit After Tax increased to ₹7,372.2 million in Q1 FY26 from ₹5,591.3 million in Q1 FY25. Consolidated Profit After Tax increased to ₹19,977.8 million from ₹15,735.6 million year-on-year.
⚙️
Operational Impact
The merger of subsidiaries indicates an effort to simplify operations and potentially integrate functions across Eugia Steriles Private Limited, Eugia SEZ Private Limited, and Eugia Pharma Specialities Limited.
⚠️
Risk Impact
The extinguishment of 5,423,728 equity shares through a buyback for ₹8,065.3 million reduced the paid-up equity share capital by ₹5.4 million, impacting capital structure.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with Basic EPS at ₹12.75 for Q1 FY26, compared to ₹9.63 in Q1 FY25. The buyback completed earlier reduced the paid-up equity share capital by ₹5.4 million.
🔍
Management Signal
The Board's decision to approve financial results and a subsidiary merger indicates a focus on operational consolidation and strategic alignment of business units.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
NCLT approval process for the proposed scheme of amalgamation
Updates on the integration of Eugia subsidiaries post-merger
Q2 FY27 financial results for revenue and profit trends
LOW RISK The filing indicates strong Q1 FY26 profit growth and a planned internal restructuring.
💡 Investor Takeaway
Aurobindo Pharma reported Q1 FY26 standalone Profit After Tax of ₹7,372.2 million, a 31.85% increase from Q1 FY25, and consolidated Profit After Tax of ₹19,977.8 million, up 27.21%. The Board approved a scheme for merging three Eugia subsidiaries.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Profit After Tax for Q1 FY26 increased by 31.85% to ₹7,372.2 million compared to ₹5,591.3 million in Q1 FY25.
  • Consolidated Profit After Tax for Q1 FY26 grew by 27.21% to ₹19,977.8 million from ₹15,735.6 million in Q1 FY25.

⚠️ Concerns

  • Standalone Revenue from Operations for Q1 FY26 decreased by 1.71% to ₹27,995.1 million from ₹28,481.7 million in Q1 FY25.
  • Changes in inventories of finished goods, stock-in-trade, and work-in-progress showed a negative figure of (₹480.5) million in standalone Q1 FY26 results.
❓ Frequently Asked Questions
What was Aurobindo Pharma's standalone Profit After Tax for Q1 FY26?
Aurobindo Pharma's standalone Profit After Tax for the quarter ended June 30, 2026, was ₹7,372.2 million.
What was the consolidated Profit After Tax for Aurobindo Pharma in Q1 FY26?
The consolidated Profit After Tax for Aurobindo Pharma for the quarter ended June 30, 2026, was ₹19,977.8 million.
What scheme of amalgamation did Aurobindo Pharma's Board approve?
Aurobindo Pharma's Board approved a scheme to merge Eugia Steriles Private Limited and Eugia SEZ Private Limited with Eugia Pharma Specialities Limited, which are all wholly-owned subsidiaries.
How did standalone revenue from operations change for Aurobindo Pharma in Q1 FY26 compared to Q1 FY25?
Standalone revenue from operations for Q1 FY26 was ₹27,995.1 million, a decrease from ₹28,481.7 million in Q1 FY25.
What was Aurobindo Pharma's standalone Basic Earnings Per Share (EPS) for Q1 FY26?
Aurobindo Pharma's standalone Basic Earnings Per Share (EPS) for the quarter ended June 30, 2026, was ₹12.75.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.